Prevention and control of proliferative vitreoretinopathy: primary retinal detachment surgery using silicone oil as a planned two-stage procedure in high-risk cases.
OBJECTIVE
For rhegmatogenous retinal detachment, reattachment with a single procedure is associated with better visual outcomes. In the past, silicone oil has been used mostly as a last resort following failed primary surgery. This study evaluates a novel approach to patients at high risk of primary failure, using silicone tamponade as the primary stage of a planned two-stage procedure.


METHODS
We report a series of 140 eyes that underwent primary surgery for rhegmatogenous retinal detachment. Patients at higher risk of surgical failure (eg giant retinal tear, inability to posture, poor view, uncertainty of location of primary break, primary proliferative vitreoretinopathy (PVR), multiple tears with rolled posterior edges, retinoschisis/detachment, staphyloma with macular hole) were managed by a planned staged procedure using primary silicone oil tamponade. This was followed by silicone removal at a later date.


RESULTS
Fifty-four eyes underwent scleral buckling alone, with primary success in 52/54 (96%). Fifty-three eyes underwent vitrectomy and gas, achieving primary success in 50/53 (94%). Thirty-three eyes were classified high risk and managed with primary silicone. Silicone was safely removed in 22/25. In eight eyes, silicone was retained without attempt at removal. In total, primary retinal reattachment was achieved in 128 of 140 eyes (91.4%). Of these, 124 (97%) did not require long-term tamponade. Only four eyes (2.9%) developed PVR.


CONCLUSIONS
A planned two-stage approach to highrisk cases of retinal detachment using primary silicone oil tamponade followed by silicone removal can achieve a high primary reattachment rate with less than 3% incidence of PVR.
Alexander
P
P
Vitreoretinal Service, Addenbrooke's Hospital, Cambridge, UK.
Prasad
R
R
Ang
A
A
Poulson
A V
AV
Scott
J D
JD
Snead
M P
MP
D035061:Control Groups; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D012160:Retina / Q000601:surgery; D012163:Retinal Detachment / Q000150:complications / Q000601:surgery*; D018570:Risk Assessment; D012591:Scleral Buckling / Q000379:methods*; D012827:Silicone Oils / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy / Q000379:methods*; D018630:Vitreoretinopathy, Proliferative / Q000150:complications / Q000517:prevention & control* / Q000601:surgery; D014822:Vitreous Body / Q000601:surgery
D012827:Silicone Oils